The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation

Medical Care

Volumn 49, Issue 2, 2011, Pages 172-179

  Carpenter, William R ^a,b,c   Reeder Hayes, Katherine ^d   Bainbridge, John ^b   Meyer, Anne Marie ^b   Amos, Keith D ^b,c,d   Weiner, Bryan J ^a,b   Godley, Paul A ^b,c,d  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c North Carolina Comprehensive Cancer Program   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; diffusion of innovation; organization and administration; provider based research networks; translational research

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; DIFFUSION; FEMALE; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT; SENTINEL LYMPH NODE BIOPSY; TEACHING; TEACHING HOSPITAL;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DIFFUSION OF INNOVATION; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE CLAIM REPORTING; INTERINSTITUTIONAL RELATIONS; LINEAR MODELS; LOGISTIC MODELS; MEDICAL ONCOLOGY; MEDICARE; MULTIVARIATE ANALYSIS; ORGANIZATIONAL AFFILIATION; PHYSICIAN'S PRACTICE PATTERNS; SEER PROGRAM; SENTINEL LYMPH NODE BIOPSY; SOCIETIES, MEDICAL; TRANSLATIONAL RESEARCH; UNITED STATES;

EID: 78751639216     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3182028ff2     Document Type: Article

References (43)

1. Balas E. Information technology and physician decision support. Program and abstracts of Accelerating Quality Improvement in Health Care: Strategies to Speed the Diffusion of Evidence-based Innovations, sponsored by National Committee for Quality Health Care; January 27-28, 2003; Washington, DC
2. Zerhouni E. The NIH Roadmap. Science. 2003;302:63-72
3. Zerhouni E. Translational and clinical science-time for a new vision. N Engl J Med. 2005;353:1621-1623
4. Lenfant C. Shattuck lecture-clinical research to clinical practice-lost in translation? N Engl J Med. 2003;349:868-874
5. Lenfant C, Claude Lenfant MD. Retiring NHLBI director looks ahead. Interviewed by Brian Vastag. JAMA. 2003;290:1017-1018
6. Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer. 2010;116:4440-4449
7. National Cancer Institute. Designing for dissemination conference summary report. Washington, DC: National Cancer Institute; 2002
8. Trans-HHS Cancer Health Disparities Progress Review Group. Making Cancer Health Disparities History-Report of the Trans-HHS Cancer Health Disparities Progress Review Group. Washington, DC: Department of Health and Human Services; 2004.
9. Lamb S, Greenlick MR, McCarty D, eds; Institute of Medicine. Bridging the Gap Between Practice and Research. Washington, DC: National Academy Press; 1998
10. National Cancer Institute. The NCI Strategic Plan for Leading the Nation to Eliminate the Suffering and Death Due to Cancer. Rockville, MD: National Cancer Institute; 2007
11. Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the National Surgical AdjuVant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71:2507-2514 (Pubitemid 23100484)
12. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187
13. Cabanes PA, Salmon RJ, Vilcoq JR, et al. The Breast Carcinoma Collaborative Group of the Institut Curie. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet. 1992;339:1245-1248
14. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol. 1999;6: 109-116
15. Chen SL, Iddings DM, Scheri RP, et al. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin. 2006;56:292-309; quiz 316-317
16. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-888
17. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983-990
18. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-553
19. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560-2566
20. Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88:608-614
21. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339:941-946
22. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-398; discussion 398-401
23. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657-3663
24. Krag D, Anderson SS, Julian TB, et al. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol. 2010;28:18; abstr LBA505
25. Chen AY, Halpern MT, Schrag NM, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100:462-474
26. Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747-1751
27. Bilimoria KY, Balch CM, Wayne JD, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27: 1857-1863
28. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327-2340
29. Keating NL, Kouri E, He Y, et al. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care. 2009;47:765-773
30. Maggard MA, Lane KE, O'Connell JB, et al. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol. 2005;12:41-47
31. Onega T, Duell EJ, Shi X, et al. Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev. 2009;66:542-560
32. Rogers E. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003
33. Sales A, Smith J, Curran G, et al. Models, strategies, and tools. Theory in implementing evidence-based findings into health care practice. J Gen Intern Med. 2006;21(suppl 2):S43-S49
34. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8): IV-3-IV-18
35. Dunn BK, Agurs-Collins T, Browne D, et al. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010;121:281-292
36. Laliberte L, Fennell ML, Papandonatos G. The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Med Care. 2005;43:471-479
37. Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530-3535
38. American College of Surgeons Commission on Cancer. Commission on cancer: about the CoC. 2010. Available at: http://www.facs.org/cancer/coc/whatis.html. Accessed June 1, 2010
39. Gooden KM, Howard DL, Carpenter WR, et al. The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy. Med Care. 2008;46:1170-1176
40. American College of Surgeons Commission on Cancer. Follow-up: DEcIDE Stakeholder Meeting-Questionnaire: ACOSOG/ACOS CoC Accreditation. Chicago, IL: WR Carpenter; 2010
41. Horner M, Ries LAG, Krapcho M, et al. SEER-Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009
42. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program [Prepublication Copy]. Washington DC: N.A. Press; 2010
43. National Cancer Institute. Report of the operational efficiency working group of the Clinical Trials and Translational Research Advisory Committee. Bethesda, MD: DHHS; 2010